Many groups around the world have studied the approach of ICIs in melanomas; most approaches were successful, while in advanced-stage melanoma patients’ application of ICIs, monoclonal antibodies CTLA-4, PD-1, and PD-L1 have produced a good response (a median survival of 5 years). Here, PDCD1 is linked to melanoma.